Alectinib, a second-generation highly selective ALK-TKI, has shown improved efficacy and tolerability compared with the first-generation ALK-TKI for the treatment of advanced ALK-positive NSCLC in both ALEX and ALISIA trials (18, 19). The gene discussed is ALK; the disease is non-small cell lung carcinoma.